A5061397748- Cancer and Skin Lesions
- Bone Tumor Diagnosis and Treatments
- Sarcoma Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Tumors and Oncological Cases
- Health Promotion and Cardiovascular Prevention
- Acute Myocardial Infarction Research
- Polyomavirus and related diseases
- Occupational and environmental lung diseases
- Cardiac Imaging and Diagnostics
- Liver Disease and Transplantation
- Coronary Interventions and Diagnostics
- Adenosine and Purinergic Signaling
- Healthcare Systems and Public Health
- Genetic and Kidney Cyst Diseases
- Cardiac Arrhythmias and Treatments
- Multiple Sclerosis Research Studies
- Biomarkers in Disease Mechanisms
- Neurofibromatosis and Schwannoma Cases
- Health Systems, Economic Evaluations, Quality of Life
- Heart Failure Treatment and Management
- Mobile Health and mHealth Applications
- Oral and Maxillofacial Pathology
- HIV/AIDS drug development and treatment
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Nini Hospital
2024
Hospital do Servidor Público Estadual
2024
University of Macerata
2023
Presidio Ospedaliero
2022
Abstract Background Plaque erosion (PE) is the second most common pathology of acute coronary events after plaque rupture. PE characterized by endothelial denudation and formation neutrophil extracellular traps. Patients with may have a different prognosis as compared to those Specific clinical laboratory predictors were validated suspect among syndrome (ACS) patients. Purpose The objectives this study compare both findings, outcomes ACS patients high probability less likely PE. Methods Six...
Abstract Background Nowadays AMI management represents one of the most challenging clinical scenarios. On 8 july 2022 ANMCO held a special event about last 20 years networks in Italy. During this it was highlighted how these – supported by led to mortality reduction (till –57%). By way, are usually based on diagnostic–therapeutic (D–T) pathways that not include NSTEMI–ACS. At contrary, prevalence NSTEMI–ACS is increasing and significantly contributes whole due coronary heart disease world....
Abstract Funding Acknowledgements Type of funding sources: None. Background Sacubitril/valsartan (S/V) has demonstrated a significant benefit in decreasing mortality and morbidity patients with heart failure reduced ejection fraction (HFrEF) when compared to angiotensin inhibition. Recent studies that the benefits S/V encompass positive cardiac remodeling, leading reduction ventricular arrhythmias. The effect on supraventricular arrhythmic burden is still unknown. Purpose To evaluate...